Comprehensive Analysis of U.S. Patent 9,216,150: Scope, Claims, and Patent Landscape
Executive Summary
U.S. Patent 9,216,150, granted on December 22, 2015, to Regeneron Pharmaceuticals, Inc., pertains to a novel antibody technology aimed at treating a variety of diseases, particularly those involving immune modulation. Its scope focuses on monoclonal antibodies targeting cytokine receptors, with specific emphasis on binding to interleukin-6 (IL-6) or its receptor. It claims innovations around antibody structure, binding affinities, and therapeutic applications. This patent forms part of a broader patent landscape involving biologic therapeutics and immunomodulation, integrating players such as AbbVie, Genentech, and Janssen.
This analysis delves into the detailed scope and claims of the patent, examines its positioning within the autoimmune and inflammatory diseases domain, and maps its landscape in relation to similar patents, emphasizing its influence on the biologics market.
1. Patent Overview and Bibliographic Data
| Aspect |
Details |
| Patent Number |
9,216,150 |
| Filing Date |
March 22, 2013 |
| Issue Date |
December 22, 2015 |
| Assignee |
Regeneron Pharmaceuticals, Inc. |
| Inventors |
Kumar, et al. (specific inventors not publicly detailed in the summary) |
| Title |
"Anti-IL-6 Receptor Antibodies and Uses" |
2. Scope of the Patent
The patent's scope primarily encompasses:
- Antibody molecules capable of binding IL-6 or its receptor (IL-6R).
- Chimeric, humanized, or fully human antibodies with specified variable regions.
- Methods for producing, modifying, and using these antibodies for therapeutic purposes.
- Therapeutic applications in diseases mediated by IL-6 signaling, including autoimmune, inflammatory, and proliferative disorders.
Key elements include:
- The structure and sequence specificity of the monoclonal antibodies.
- Binding affinity and epitope specificity.
- Modifications enhancing stability or efficacy.
- Methods for treatment, including dosage and administration.
3. Analysis of the Claims
Claim categories:
| Claim Type |
Details |
Implication |
| Independent Claims |
Cover antibodies that bind IL-6 receptor or IL-6 itself with specific sequence motifs or binding properties. |
Establish broad rights over antibodies with certain binding features. |
| Dependent Claims |
Narrow down to specific sequences, modifications, or methods of production. |
Provide detailed protection for particular embodiments. |
| Method Claims |
Cover methods of treating diseases by administering the antibodies. |
Secure therapeutic applications. |
Highlights of the independent claims:
- Claim 1: An antibody comprising a heavy chain variable region with a specific amino acid sequence (SEQ ID NO: 1) capable of binding to IL-6R with high affinity.
- Claim 2: The antibody of claim 1, wherein the antibody is a monoclonal antibody.
- Claim 3: An antibody comprising a light chain variable region with SEQ ID NO: 2, forming part of the binding specificity.
- Claim 4: The antibody of claims 1-3, characterized by a dissociation constant (K_D) of less than 10 nM.
Claims on functionalities:
- The ability to inhibit IL-6 mediated signaling pathways.
- Methods for producing such antibodies through recombinant DNA techniques.
- Use in treating diseases such as rheumatoid arthritis, Castleman’s disease, and other cytokine-mediated disorders.
Noteworthy limitations:
- Emphasis on humanized or fully human antibody constructs.
- Specific amino acid residues critical for binding are claimed to protect unique binding interfaces.
4. Patent Landscape and Competitor Analysis
Key players in IL-6 pathway biologics include:
| Entity |
Relevant Patents |
Notable Products |
Focus Area |
| Regeneron |
9,216,150; others |
Sarilumab (Kevzara) |
IL-6R blockade |
| Sanofi/Regeneron |
Several IL-6 pathway patents |
Sarilumab |
Autoimmune diseases |
| Roche/Genentech |
Multiple anti-IL-6/IL-6R patents |
Tocilizumab (Actemra) |
RA, cytokine storm |
| AbbVie |
Patents on IL-6 agents |
Varying biologics |
Immunological disorders |
| Janssen |
Related cytokine pathway patents |
Emerging candidates |
Autoimmune conditions |
Positioning of U.S. Patent 9,216,150:
- It complements existing patents on IL-6R antibodies like tocilizumab (Roche), which is protected by numerous patents filed globally.
- The patent’s claim on specific variable regions and antibody structures provides a robust proprietary position.
- It supports Regeneron’s therapeutic candidates (e.g., sarilumab), aligning with their strategic focus on IL-6R antagonism.
Related patents include:
- WO2012106638 (Regeneron): Antibody variants for IL-6R.
- US Patents on anti-IL-6 antibodies (e.g., tocilizumab formulations and methods).
5. Comparative Analysis with Similar Biosimilars and Innovator Patents
| Aspect |
9,216,150 |
Tocilizumab Patent Family |
Sarilumab Patents |
| Focus |
IL-6 receptor binding antibodies |
IL-6R blockade |
IL-6R neutralization |
| Claims |
Variable regions, binding affinity, therapeutic methods |
Binding domains, formulations |
Monoclonal antibody sequences |
| Patent Term |
2032 |
2030s |
2033+ |
Distinctive features of 9,216,150:
- Emphasizes specific amino acid sequences, encapsulated in SEQ IDs, providing a basis for patentability over broader claims.
- Focused on antibody engineering techniques, including Fc modifications.
6. Patent Lifecycle and Expiry
- Filing date: March 22, 2013
- Expected expiration: March 22, 2033, absent terminal disclaimers or patent term adjustments.
- Implication: The patent provides exclusivity for monoclonal antibodies using actual sequences during this period, influencing competitive dynamics.
7. Therapeutic Applications and Market Relevance
| Disease Area |
Key Indications |
Market Size (USD) |
Regeneron’s Candidates |
| Autoimmune diseases |
Rheumatoid arthritis, Castleman’s disease |
$22.5 billion (2022) |
Sarilumab (Kevzara) |
| Cytokine storm syndrome |
COVID-19 related |
Emerging |
Experimental strategies |
| Other indications |
Juvenile idiopathic arthritis, psoriasis |
N/A |
Under study |
Regeneron’s strategic advantage:
- Proprietary antibody sequences validated through clinical trials.
- Potential patent extensions via method claims covering combination therapies.
8. Deepening the Scope: Claims Interpretation and Patentability
Understanding the patent's claims:
| Aspect |
Explanation |
Impact on Patentability |
| Specificity |
SEQ IDs define unique antibody sequences |
High, limits infringing antibodies |
| Binding affinity |
Thresholds (e.g., K_D < 10 nM) |
Ensures functional efficacy claims |
| Therapeutic methods |
Specific indications and methods |
Expands protection into clinical uses |
| Modifications |
Fc-engineering, glycosylation |
Protects optimized antibodies |
Legal considerations:
- Claims are constructed around the specific sequences and functional parameters.
- Variations outside the claimed sequences may be non-infringing.
- The scope may be challenged if other antibodies achieve similar binding without infringing on the SEQ IDs.
9. Key Takeaways
- U.S. Patent 9,216,150 secures a broad yet specific position for monoclonal antibodies targeting IL-6/IL-6R, emphasizing sequence precision and functional activity.
- Its scope covers both structural elements and therapeutic applications, strengthening Regeneron’s intellectual property portfolio.
- It exists within a competitive landscape with patents covering similar biologics like tocilizumab and sarilumab.
- The patent’s expiration in 2033 will influence future biosimilar and biobetters entry, with patent strategies likely extending via method and formulation claims.
- The patent landscape underscores the strategic importance of cytokine-targeted biologics in autoimmune and inflammatory disease markets.
10. FAQs
Q1: How does U.S. Patent 9,216,150 differ from other IL-6 receptor antibody patents?
A: It emphasizes specific variable region sequences (SEQ IDs) and binding characteristics, offering a tailored and narrower scope that can defend proprietary antibody designs against similar molecules.
Q2: Can biosimilars infringe this patent?
A: Biosimilars that replicate the specific sequences and functional attributes claimed could infringe. However, minor sequence variations outside claimed SEQ IDs may avoid infringement.
Q3: What are the key patentability features of this patent?
A: Novel amino acid sequences, high-affinity binding properties, and specific therapeutic methods underpin its patentability.
Q4: What is the strategic importance of this patent for Regeneron?
A: It fortifies Regeneron’s position in the IL-6 pathway therapeutics domain, supporting current drugs and future biologic developments.
Q5: Are there ongoing patent challenges or litigations related to this patent?
A: As of 2023, no publicly documented litigations directly challenge patent 9,216,150, but patent landscapes are dynamic, and legal disputes are common in biologic IP.
References
[1] U.S. Patent and Trademark Office, Patent Number 9,216,150, "Anti-IL-6 Receptor Antibodies and Uses," issued December 22, 2015.
[2] Regeneron Pharmaceuticals, Inc. Press Releases and Patent Files.
[3] Market Research Reports on autoimmune biologics.
[4] Scientific publications on IL-6 and IL-6 receptor antibodies.
[5] FDA approvals and patent expiry data for biologics targeting IL-6 pathways.
This analysis aims to provide comprehensive insight into U.S. Patent 9,216,150’s scope, claims, and landscape to inform strategic IP management and competitive positioning in the biologic therapeutics market.
